Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 16

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 16
---
 including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma, is a liquid formulation of the histone deacetylase, panobinostat. Our proprietary formulation enables delivery of the product via convection-enhanced delivery at potentially chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and avoiding systemic toxicity. We completed recruitment of the first cohort of patients in an ongoing Phase 1 study of MTX110 in recurrent glioblastoma. We have also completed and announced the results of two Phase 1 studies in DMG. There is an ongoing Phase 1 investigator-initiated trial in medulloblastoma. Due to resource constraints, MTX110 has been de-prioritized. Our clinical assets are supported by three proprietary drug delivery technologies focused on improving bio-delivery and bio-distribution of drugs through either sustained delivery (Q-Sphera TM), direct delivery (MidaSolve TM), or targeted delivery (MidaCore TM):

| · | Our Q-Sphera platform: Our disruptive polymer microsphere microtechnology                                                                
 is used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. |

| · | Our MidaSolve platform: Our innovative oligosaccharide nanotechnology                                         
 is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors. |

| · | MidaCore platform: Our gold nanoparticle nanotechnology is used                                     
 for targeting sites of disease by using either chemotherapeutic agents or immunotherapeutic agents. |

We are currently focused on our clinical stage assets eRapa and tolimidone and there are no active research and development programs based on our drug delivery technologies. Financial Update As of September 30, 2025, we had cash and cash equivalents of £2.79 million. Financial information as of September 30, 2025 in this prospectus has not been audited and has been prepared by, and is the responsibility of, our management. This data could change as a result of further review. In addition, our independent registered public accounting firm has not audited, reviewed, compiled, or performed any procedures with respect to this unaudited financial information and does not express an opinion or any other form of assurance with respect thereto. Accordingly, you should not place undue reliance on this information. Additional information and disclosures would be